Alliance Medical of Oxfordshire and M2i of Dublin have formed a joint venture to produce and distribute PET radiopharmaceuticals in the U.K. The new company, called Molecular Imaging Services, will focus on the production of F-18 FDG (fluorodeoxyglucose)
Alliance Medical of Oxfordshire and M2i of Dublin have formed a joint venture to produce and distribute PET radiopharmaceuticals in the U.K. The new company, called Molecular Imaging Services, will focus on the production of F-18 FDG (fluorodeoxyglucose) through a series of dedicated radiopharmaceutical production units. These units will serve both hospital-based PET facilities and mobile PET scanners. Alliance Medical operates two PET scanners in the U.K.: a stationary unit at a facility located in London and a mobile PET scanner serving three hospitals. The mobile PET will soon begin serving a fourth hospital.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Assessing MACE Risk in Women: Can an Emerging Model with SPECT MPI Imaging Have an Impact?
December 9th 2024In research involving over 2,200 women who had SPECT MPI exams, researchers found that those who had a high score with the COronary Risk Score in WOmen (CORSWO) model had a greater than fourfold higher risk of major adverse coronary events (MACE).